New scientific advisors bring expertise in cell therapy development, surgery & transplantation, liver disease, diabetes, and biomaterials VANCOUVER, BC — Aspect Biosystems, a biotechnology company pioneering the development of bioengineered… Read More
Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant efficacy improvement in patients ages… Read More
CALGARY, AB & MOUNTAIN VIEW, CA – Willow Biosciences Inc. (“Willow” or the “Company”) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients… Read More
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible… Read More
VANCOUVER, BC –– InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the closing of its… Read More
